ABBVIE INC.

ABBV

AbbVie Inc. (ABBV) is a global biopharmaceutical company founded in 2013 as a spin-off from Abbott Laboratories. It specializes in the research, development, and marketing of innovative medicines across a range of therapeutic areas, including immunology, oncology, virology, and neuroscience. AbbVie is known for its flagship product, Humira, a leading treatment for autoimmune diseases. The company focuses on advancing scientific discoveries to deliver novel therapies and improve patient outcomes worldwide.

$222.03 +0.47 (0.21%)

Dividend Yield 3.04%

Payout Frequency Quarterly

Dividend History

Pay Date	Amount	Ex-Date	Record Date
May 15, 2026	$1.73	2026-04-15	2026-04-15
February 17, 2026	$1.73	2026-01-16	2026-01-16
November 14, 2025	$1.64	2025-10-15	2025-10-15
August 15, 2025	$1.64	2025-07-15	2025-07-15
May 15, 2025	$1.64	2025-04-15	2025-04-15
February 14, 2025	$1.64	2025-01-15	2025-01-15
November 15, 2024	$1.55	2024-10-15	2024-10-15
August 15, 2024	$1.55	2024-07-15	2024-07-15
May 15, 2024	$1.55	2024-04-12	2024-04-15
February 15, 2024	$1.55	2024-01-12	2024-01-16
November 15, 2023	$1.48	2023-10-12	2023-10-13
August 15, 2023	$1.48	2023-07-13	2023-07-14
May 15, 2023	$1.48	2023-04-13	2023-04-14
February 15, 2023	$1.48	2023-01-12	2023-01-13
November 15, 2022	$1.41	2022-10-13	2022-10-14
August 15, 2022	$1.41	2022-07-14	2022-07-15
May 16, 2022	$1.41	2022-04-13	2022-04-15
February 15, 2022	$1.41	2022-01-13	2022-01-14
November 15, 2021	$1.30	2021-10-14	2021-10-15
August 16, 2021	$1.30	2021-07-14	2021-07-15
May 14, 2021	$1.30	2021-04-14	2021-04-15
February 16, 2021	$1.30	2021-01-14	2021-01-15
November 16, 2020	$1.18	2020-10-14	2020-10-15
August 14, 2020	$1.18	2020-07-14	2020-07-15
May 15, 2020	$1.18	2020-04-14	2020-04-15
February 14, 2020	$1.18	2020-01-14	2020-01-15
November 15, 2019	$1.07	2019-10-11	2019-10-15
August 15, 2019	$1.07	2019-07-12	2019-07-15
May 15, 2019	$1.07	2019-04-12	2019-04-15
February 15, 2019	$1.07	2019-01-14	2019-01-15
November 15, 2018	$0.96	2018-10-12	2018-10-15
August 15, 2018	$0.96	2018-07-12	2018-07-13
May 15, 2018	$0.96	2018-04-12	2018-04-13
February 15, 2018	$0.71	2018-01-11	2018-01-12
November 15, 2017	$0.64	2017-10-12	2017-10-13
August 15, 2017	$0.64	2017-07-12	2017-07-14
May 15, 2017	$0.64	2017-04-11	2017-04-13
February 15, 2017	$0.64	2017-01-11	2017-01-13
November 15, 2016	$0.57	2016-10-12	2016-10-14
August 15, 2016	$0.57	2016-07-13	2016-07-15
May 16, 2016	$0.57	2016-04-13	2016-04-15
February 16, 2016	$0.57	2016-01-13	2016-01-15
November 14, 2015	$0.51	2015-10-13	2015-10-15
August 14, 2015	$0.51	2015-07-13	2015-07-15
May 15, 2015	$0.51	2015-04-13	2015-04-15
February 13, 2015	$0.49	2015-01-13	2015-01-15
November 17, 2014	$0.42	2014-10-10	2014-10-15
August 15, 2014	$0.42	2014-07-11	2014-07-15
May 15, 2014	$0.42	2014-04-11	2014-04-15
February 14, 2014	$0.40	2014-01-13	2014-01-15
November 15, 2013	$0.40	2013-10-10	2013-10-15
August 15, 2013	$0.40	2013-07-11	2013-07-15
May 15, 2013	$0.40	2013-04-11	2013-04-15
February 15, 2013	$0.40	2013-01-11	2013-01-15

Dividends Summary

Consistent Payer: ABBVIE INC. has rewarded shareholders with 54 dividend payments over the past 13 years.
Total Returned Value: Investors who held ABBV shares during this period received a total of $55.69 per share in dividend income.
Latest Payout: The most recent dividend of $1.73/share was paid 32 days ago, on May 15, 2026.
Yield & Schedule: ABBV currently pays dividends quarterly with an annual yield of 3.04%.
Dividend Growth: Since 2013, the dividend payout has grown by 332.5%, from $0.40 to $1.73.
Dividend Reliability: ABBV has maintained or increased its dividend for 54 consecutive payments.

Company News

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

GlobeNewswire Inc. • Genmab A/S • June 13, 2026

Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab in elderly DLBCL patients. The monotherapy arm (EPCORE DLBCL-3) showed 67% overall response rate and 58% complete response rate, while the combination with R-mini-CHOP (EPCORE NHL-2) demonstrated 93% overall response rate and 86% complete response rate with durable rem...

GMAB

The Motley Fool • Alex Carchidi • June 12, 2026

Teva Pharmaceutical has rebounded 97% in 12 months driven by its expanding biosimilars lineup and branded drugs like Austedo. However, the stock now trades at a fair 25x P/E ratio with 2026 revenue expected to be flat to lower. While biosimilars could grow to $800 million by 2027, the narrow-margin business faces intense competition and the easy ...

TEVA ALVO ALVOW

AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients

Benzinga • Vandana Singh • June 12, 2026

AbbVie announced nine-year Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab significantly improved progression-free survival (6.4 years vs 3.2 years) compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients. The fixed-duration combination demonstrated median time to next treatment of 7....

XLV

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

The Motley Fool • Jeff Siegel • June 12, 2026

AbbVie presented 21 clinical presentations on blood cancer therapies at the European Hematology Association Congress, showcasing progress in its oncology portfolio which generated $6.7 billion in 2025 revenue. The company's diversified pipeline across immunology, oncology, and neuroscience is helping offset Humira's patent-driven decline and coul...

LLY JNJ AMGN

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

The Motley Fool • Brendan Coffey • June 8, 2026

The article compares two biotech companies with contrasting profiles: Kyverna Therapeutics, a clinical-stage firm developing cell therapies for autoimmune diseases with no approved products and significant losses, versus Vertex Pharmaceuticals, an established leader generating $12 billion in revenue with a dominant cystic fibrosis franchise. The ...

KYTX VRTX